Literature DB >> 11359081

Frequency of multiple sclerosis in Menorca, Balearic islands, Spain.

P Casquero1, P Villoslada, X Montalbán, M Torrent.   

Abstract

OBJECTIVE: To establish prevalence and incidence of multiple sclerosis (MS) in Menorca (Balearic Islands, Spain; population: 67,009).
METHODS: An extensive epidemiological study was undertaken using all available information sources. Patients were classified according to Poser's criteria.
RESULTS: The prevalence rate of definite and probable MS was 68.6/100,000 (95% confidence interval 50.3-91.6). The incidence rate was 3.4/100,000/year (95% CI 2.2-5.3). The time lag between the first symptom and diagnosis was 10.2 years for patients with disease onset before 1987 and 2.1 years for patients with onset between 1987 and 1996.
CONCLUSION: Menorca's population has a moderately high MS risk, with a prevalence rate the highest reported for a Spanish region. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2001        PMID: 11359081     DOI: 10.1159/000054772

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  3 in total

1.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

Review 2.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

3.  Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil.

Authors:  Vijayalakshmi Vasanthaprasad; Vivek Khurana; Sreelatha Vadapalle; Jackie Palace; Nicholas Adlard
Journal:  BMC Neurol       Date:  2022-08-17       Impact factor: 2.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.